Blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Manon QueudevillePatrick SchlegelAmadeus T HeinzTeresa LenzMichaela DöringUrsula HolzerUlrike HartmannHermann KreyenbergArend von StackelbergMartin SchrappeGerhard ZugmaierTobias FeuchtingerPeter LangRupert HandgretingerMartin EbingerPublished in: European journal of haematology (2021)
Despite heavy pretreatment of most of our patients, severe adverse events were rare and response rates encouraging. Blinatumomab is a valuable bridging salvage therapy for relapsed or refractory patients to a second or even third HSCT.